Boston Scientific Logo

Drug-Eluting Stent Clinical Program

TAXUS(R) Stent SystemBoston Scientific’s drug-eluting stent (DES) program is one of the most rigorous and comprehensive in the industry. Beginning with the TAXUS clinical program in 2001, we have continually led the way in collecting and providing solid clinical evidence for the safety, efficacy and value of our DES products.

Since the launch of the TAXUS® Stent System, Boston Scientific has continued to innovate with improved stent design and features. We are also the only company to offer two distinct drug platforms. Throughout our DES development process, we have supported each program with carefully designed clinical trials and registries, intended to provide relevant data for physicians making clinical decisions in routine interventional practice.


DES Clinical Trial Program

DES Clinical Trial Program

 

The Promus Stent is a private-labeled Xience V® Everolimus Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. Xience V is a trademark of the Abbott Laboratories group of companies.